Amarin announces new data from REDUCE-IT trial, abstracts

Amarin Corporation announced new supported and/or funded subgroup data from the landmark REDUCE-IT cardiovascular outcomes trial with VASCEPA/VAZKEPA, as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid that will be presented at the European Society of Cardiology, ESC, Congress in London, United Kingdom, August 30 – September 2, 2024. The accepted abstracts include a REDUCE-IT subgroup analysis to assess if baseline small dense low density lipoprotein cholesterol modifies the effect of icosapent ethyl on cardiovascular events. A second abstract examines the association of triglycerides with cardiovascular events in patients with initial or recurrent acute coronary syndrome. A third abstract estimates the number of ACS patients eligible for IPE in Spanish hospitals, and finally, a fourth abstract measures the effects of EPA on oxidation of Lp under experimental conditions of high glucose.